A citation-based method for searching scientific literature

Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou. Lancet Oncol 2019
Times Cited: 135



Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna M Calella, Gerson Peltz, Benjamin J Solomon. N Engl J Med 2020
Times Cited: 209




List of shared articles



Times cited

Post-chemotherapy and targeted therapy imaging of the chest in lung cancer.
B W Carter, M Altan, G S Shroff, M T Truong, I Vlahos. Clin Radiol 2022
1

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Jennifer E Hibma, Melissa O'Gorman, Sunil Nepal, Sylvester Pawlak, Katherine Ginman, Yazdi K Pithavala. Cancer Chemother Pharmacol 2022
1


Managing Central Nervous System Spread of Lung Cancer: The State of the Art.
David Chun Cheong Tsui, D Ross Camidge, Chad G Rusthoven. J Clin Oncol 2022
2

Complications following novel therapies for non-small cell lung cancer.
Marcus Skribek, Konstantinos Rounis, Georgios Tsakonas, Simon Ekman. J Intern Med 2022
0

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Yuankai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li,[...]. Signal Transduct Target Ther 2022
1

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
1

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).
María Martínez-García, Sonia Servitja Tormo, Noelia Vilariño Quintela, Ana Arance Fernández, Alfonso Berrocal Jaime, Blanca Cantos Sánchez de Ibargüen, Sonia Del Barco Berrón, Rosario García Campelo, Regina Gironés Sarrió, Juan Manuel Sepúlveda-Sánchez. Clin Transl Oncol 2022
2

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
David J Benjamin, Alyson Haslam, Jenny Gill, Vinay Prasad. Cancer Med 2022
0


Intracranial Metastatic Disease: Present Challenges, Future Opportunities.
Alyssa Y Li, Karolina Gaebe, Katarzyna J Jerzak, Parneet K Cheema, Arjun Sahgal, Sunit Das. Front Oncol 2022
0


Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022
0

Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.
Christopher Alvarez-Breckenridge, Jordi Remon, Yolanda Piña, Edwin Nieblas-Bedolla, Peter Forsyth, Lizza Hendriks, Priscilla K Brastianos. Am Soc Clin Oncol Educ Book 2022
0

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.
Fabrizio Tabbò, Marco DE Filippis, Francesca Jacobs, Silvia Novello. Minerva Med 2022
0

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Ross A Soo, Eng Huat Tan, Hidetoshi Hayashi, Takashi Seto, Chia-Chi Lin, Sai-Hong Ignatius Ou, Dong-Wan Kim, Geoffrey Liu, Antonello Abbattista, Jean-François Martini,[...]. Lung Cancer 2022
0

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era.
Elisa De Carlo, Elisa Bertoli, Alessandro Del Conte, Brigida Stanzione, Eleonora Berto, Alberto Revelant, Michele Spina, Alessandra Bearz. Int J Mol Sci 2022
0

Targeting molecular alterations in non-small-cell lung cancer: what's next?
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita. Per Med 2022
0

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
80

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
9

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
12

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Sergey V Orlov, Aglaya G Iyevleva, Elena A Filippova, Alexandra M Lozhkina, Svetlana V Odintsova, Tatiana N Sokolova, Natalia V Mitiushkina, Vladislav I Tiurin, Elena V Preobrazhenskaya, Alexandr A Romanko,[...]. Transl Oncol 2021
2

Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.
Alessia Pellerino, Priscilla K Brastianos, Roberta Rudà, Riccardo Soffietti. Cancers (Basel) 2021
5


First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
Tania Losanno, Cesare Gridelli. Curr Oncol Rep 2021
0

Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff. Nat Med 2021
44

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Leora Horn, Ziping Wang, Gang Wu, Elena Poddubskaya, Tony Mok, Martin Reck, Heather Wakelee, Alberto A Chiappori, Dae Ho Lee, Valeriy Breder,[...]. JAMA Oncol 2021
25


Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
3

Systemic Therapy for Lung Cancer Brain Metastases.
Alessia Pellerino, Francesco Bruno, Roberta Rudà, Riccardo Soffietti. Curr Treat Options Oncol 2021
0

Recent advances in lung cancer genomics: Application in targeted therapy.
Neha Pathak, Sindhura Chitikela, Prabhat Singh Malik. Adv Genet 2021
1

Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies.
Nathaniel J Myall, Helena Yu, Scott G Soltys, Heather A Wakelee, Erqi Pollom. Neurooncol Adv 2021
0